Compare Stocks: IMMX, LEGN, GRAL, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$17.11 -5.3%	$24.00	$11.92 ▼ $27.31	$3.20B	1.08	2.97 million shs	4.85 million shs
GRAL GRAIL	$80.77 +1.0%	$74.12	$39.29 ▼ $118.84	$3.61B	3.25	700,928 shs	3.00 million shs
IMMX Immix Biopharma	$12.50 -1.7%	$11.41	$1.98 ▼ $15.10	$894.24M	0.2	1.36 million shs	4.18 million shs
LEGN Legend Biotech	$17.61 +0.2%	$20.76	$16.24 ▼ $37.50	$3.41B	0.4	1.83 million shs	2.94 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	0.00%	-6.04%	-34.14%	-13.59%	+30.11%
GRAL GRAIL	0.00%	+5.96%	+3.59%	+26.72%	+110.78%
IMMX Immix Biopharma	0.00%	+2.97%	-5.02%	+43.35%	+537.76%
LEGN Legend Biotech	0.00%	-5.53%	-17.17%	-36.95%	-48.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$17.11 -5.3%	$24.00	$11.92 ▼ $27.31	$3.20B	1.08	2.97 million shs	4.85 million shs
GRAL GRAIL	$80.77 +1.0%	$74.12	$39.29 ▼ $118.84	$3.61B	3.25	700,928 shs	3.00 million shs
IMMX Immix Biopharma	$12.50 -1.7%	$11.41	$1.98 ▼ $15.10	$894.24M	0.2	1.36 million shs	4.18 million shs
LEGN Legend Biotech	$17.61 +0.2%	$20.76	$16.24 ▼ $37.50	$3.41B	0.4	1.83 million shs	2.94 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	0.00%	-6.04%	-34.14%	-13.59%	+30.11%
GRAL GRAIL	0.00%	+5.96%	+3.59%	+26.72%	+110.78%
IMMX Immix Biopharma	0.00%	+2.97%	-5.02%	+43.35%	+537.76%
LEGN Legend Biotech	0.00%	-5.53%	-17.17%	-36.95%	-48.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	2.81	Moderate Buy	$32.17	88.00% Upside
GRAL GRAIL	2.33	Hold	$70.30	-12.96% Downside
IMMX Immix Biopharma	2.78	Moderate Buy	$22.86	82.86% Upside
LEGN Legend Biotech	2.47	Hold	$53.14	201.78% Upside

Current Analyst Ratings Breakdown

Latest IMMX, LEGN, GRAL, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/15/2026	IMMX Immix Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $26.00
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $26.00
9/9/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$35.00 ➝ $30.00
9/9/2026	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $10.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
GRAL GRAIL	$147.17M	24.52	N/A	N/A	$66.13 per share	1.22
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
LEGN Legend Biotech	$1.03B	3.32	N/A	N/A	$5.43 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.05	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)

Latest IMMX, LEGN, GRAL, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	0.28	12.02	12.02
GRAL GRAIL	N/A	10.95	10.95
IMMX Immix Biopharma	N/A	25.13	25.13
LEGN Legend Biotech	N/A	3.04	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
GRAL GRAIL	N/A
IMMX Immix Biopharma	11.26%
LEGN Legend Biotech	70.89%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	9.46%
GRAL GRAIL	1.83%
IMMX Immix Biopharma	30.30%
LEGN Legend Biotech	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
IMMX Immix Biopharma	21	71.54 million	49.86 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable

IMMX, LEGN, GRAL, and DYN Headlines

Recent News About These Companies

Legend names Ingrid Zhang as CEO

September 17 at 7:02 PM | thepharmaletter.comT

LEGN’s new CEO from Novartis paves way for buyout speculation

September 15, 2026 | msn.com

Legend Biotech Appoints Ingrid Zhang as CEO

September 15, 2026 | finance.yahoo.com

Legend Biotech taps Novartis veteran Zhang as CEO

September 15, 2026 | reuters.com

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

September 15, 2026 | globenewswire.com

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

September 15, 2026 | wsj.com

Tidal Investments LLC Purchases 61,023 Shares of Legend Biotech Corporation Sponsored ADR $LEGN

September 13, 2026 | marketbeat.com

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

Wellington Management Group LLP Acquires New Position in Legend Biotech Corporation Sponsored ADR $LEGN

September 11, 2026 | marketbeat.com

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

September 10, 2026 | globenewswire.com

Squarepoint Ops LLC Raises Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

September 9, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Raiffeisen Bank International AG

September 5, 2026 | marketbeat.com

Legend Biotech's (LEGN) Buy Rating Reiterated at HC Wainwright

September 4, 2026 | marketbeat.com

Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?

September 2, 2026 | finance.yahoo.com

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 1, 2026 | globenewswire.com

Legend Biotech Corporation Sponsored ADR $LEGN is Montanova Capital LLC's 4th Largest Position

September 1, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Hold" from Brokerages

September 1, 2026 | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Trading Up 4.8% - Here's Why

August 31, 2026 | marketbeat.com

Bank of America Corp DE Trims Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

August 31, 2026 | marketbeat.com

Legend Biotech Corporation (LEGN)

August 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMMX, LEGN, GRAL, and DYN Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$17.11 -0.95 (-5.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.11 +0.00 (+0.03%)

As of 09/18/2026 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

GRAIL NASDAQ:GRAL

$80.77 +0.82 (+1.03%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$80.96 +0.19 (+0.23%)

As of 09/18/2026 07:31 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Immix Biopharma NASDAQ:IMMX

$12.50 -0.22 (-1.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 0.00 (0.00%)

As of 09/18/2026 07:36 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Legend Biotech NASDAQ:LEGN

$17.61 +0.03 (+0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.73 +0.12 (+0.65%)

As of 09/18/2026 07:41 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, LEGN, GRAL, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, LEGN, GRAL, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, LEGN, GRAL, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMX, LEGN, GRAL, and DYN Company Descriptions

Dyne Therapeutics NASDAQ:DYN

GRAIL NASDAQ:GRAL

Immix Biopharma NASDAQ:IMMX

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, LEGN, GRAL, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, LEGN, GRAL, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, LEGN, GRAL, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMX, LEGN, GRAL, and DYN Company Descriptions

Dyne Therapeutics NASDAQ:DYN

GRAIL NASDAQ:GRAL

Immix Biopharma NASDAQ:IMMX

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools